Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

responses and PFS demonstrated by pixantrone are currently not achievable using standard of care and we would welcome the opportunity to utilize this new drug for the benefit of our patients."

The poster from the conference is available at www.celltherapeutics.com/investor_updates.

To demonstrate that the dose and schedule utilized in the PIX301 trial and proposed for the follow on PIX306 study, is an appropriate dose and exposure for maximizing efficacy while minimizing side effects, the Company had an expert pharmacokinetic exposure safety and efficacy analysis conducted on data from all of its phase I, II and III trials including relapsed refractory patients with solid tumor malignancies. At an investor meeting at ASH those data were presented demonstrating that the dose of pixantrone used in PIX301 and proposed for PIX306 is an appropriate dose demonstrating a significant correlation between exposure to pixantrone and enhanced anti-tumor response (Progression-Free Survival ("PFS")) while minimizing the risk for side effects (neutropenia). The PIX306 trial is currently planned to be a randomized, single-blind study comparing pixantrone + rituximab to combination gemcitabine + rituximab in patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ("NHL") who are not candidates for myeloablative chemotherapy and stem cell transplant.

A summary status update on the PIX203 front line trial of CPOP-rituximab versus CHOP-rituximab in high risk and elderly DLBCL was also presented at an investigator meeting at ASH. Given that median PFS has not yet been reached for the CPOP-R arm and the median OS has not yet been reached for both treatment arms the Company only provided a brief update on patient demographics, while summarizing key efficacy and safety endpoints of the study. The Company anticipates submitting the PIX203 data for presentation at scientific meetings
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.Y. , May 22, 2013  Empire ... license for a patent pending novel genomic biomarker ... molecular diagnostic test that could help in diagnosing ... prostate cancer.  Neuroendocrine prostate cancer ... (PCA) that can arise de novo, but more ...
(Date:5/22/2013)... and NEW ORLEANS , May ... the field of regenerative medicine, presented new data generated ... Analysis Group (a leading health economics consultancy) demonstrating the ... ulcers (DFU) and venous leg ulcers (VLU) place upon ... of this research, which reveal annual costs of up ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) ... the Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer ... programs on May 30 at 1:30 p.m. Eastern Time.  A ... available on the Investors page of the Cleveland BioLabs website ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Mold remediation could ... said that there is a way to cut down the ... on its latest post the details of a method ... money. , Mold could be prevented, My Cleaning Products said. ... company stated that a mold remediation must then be promptly ...
Breaking Biology Technology:Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... will present a,company update at the BioCentury NewsMakers ... on Thursday, September 6, 2007 at 10:30 a.m.,ET. ... webcast of the presentation,via the investor section of ...
... Thursday, September 6, 2007, SAN DIEGO, Aug. ... announced today that Neurocrine Biosciences will,present at the ... presentation takes place Thursday, September 6, 2007 at ... (PT). The presentation will be,simultaneously webcast and may ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) ... its first patent by the Canadian Intellectual ... (Number,2,259,318), this issuance extends the coverage of ... issued in the United States,Japan, Germany, Italy, ...
Cached Biology Technology:Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
(Date:5/21/2013)... stem cells in the blood often jump into ... cells that can fight off illness. But repeated ... potentially leading to the development of serious blood ... researchers led by biologists at the California Institute ... models, the molecule microRNA-146a (miR-146a) acts as a ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... of 154 smokers who had surgery to remove early stage ... of their potentially curative operation, and more than one-third ... patients who started smoking again did so within two months ... University School of Medicine and published in the December issue ...
... of researchers from Arizona State University and Motorola Labs, ... sensors based on carbon nanotubes, microscopically small structures that ... devices detected the presence of heavy metal ions in ... the researchers developed a method for applying peptides to ...
... risky behavior for humans, it's healthy for honeybees: Queen ... produce more disease-resistant colonies than monogamous monarchs. , According ... 7 issue of the Proceedings of the Royal Society ... long perplexed apiculturists, especially since seeking out multiple mates ...
Cached Biology News:Successful lung cancer surgery not enough to break nicotine dependence in many smokers 2Successful lung cancer surgery not enough to break nicotine dependence in many smokers 3Motorola researchers develop selective sensors based on carbon nanotubes 2Queen bee promiscuity boosts hive health 2
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
...
Biology Products: